Scilex Holding Company announced a major initiative with a leading national pharmacy chain to stock GLOPERBA in most of their stores throughout the U.S. GLOPERBA, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is expected to launch in the U.S. in first half of 2024. The increase of GLOPERBA manufacturing is to meet its potential demand and increased stocking needs in its distribution center. “GLOPERBA is a highly complementary commercial asset that allows the Company to provide physicians with another tool in their non-opioid pain management armamentarium to treat gout earlier in the patient journey as the Company continues to work towards re-defining the role of opioids as a last resort pain medication,” said Jaisim Shah, Chief Executive Officer and President of Scilex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCLX:
- Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)
- Virpax announces settlement of litigation with Sorrento and Scilex
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
- Scilex announces over 1M patients treated with ZTlido since launch
- Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone – Over One Million Patients Treated Since its Launch – and Two Additional Milestones Met